Enliven Therapeutics Inc
(ELVN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 48,309 | 75,295 | 48,037 | 53,441 | 47,698 |
| Marketable Securities | 41,969 | 27,544 | 18,731 | 22,151 | 40,524 |
| TOTAL | $92,696 | $105,997 | $71,357 | $80,361 | $90,405 |
| Non-Current Assets | |||||
| PPE Net | 250 | 275 | 299 | 324 | 349 |
| Other Non-Current Assets | 700 | 755 | 812 | 1,002 | 88 |
| TOTAL | $950 | $1,030 | $1,111 | $1,326 | $437 |
| Total Assets | $93,646 | $107,027 | $72,468 | $81,687 | $90,842 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,360 | 2,476 | 2,626 | 3,001 | 1,971 |
| Accrued Expenses | 4,604 | 4,462 | 4,093 | 2,245 | 4,276 |
| TOTAL | $7,210 | $7,188 | $6,973 | $5,503 | $6,247 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 406 | 466 | 528 | 590 | 0 |
| TOTAL | $406 | $466 | $528 | $590 | $160 |
| Total Liabilities | $7,616 | $7,654 | $7,501 | $6,093 | $6,407 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 6,572 | 6,569 | 6,562 | 4,410 | 4,394 |
| Common Shares | 27 | 27 | 19 | 18 | 18 |
| Retained earnings | -147,497 | -133,178 | -119,531 | -106,370 | -96,113 |
| Other shareholders' equity | -16 | -2 | 0 | 1 | 4 |
| TOTAL | $86,030 | $99,373 | $64,967 | $75,594 | $84,435 |
| Total Liabilities And Equity | $93,646 | $107,027 | $72,468 | $81,687 | $90,842 |